Clinical Trials Logo

Metastatic Solid Tumors clinical trials

View clinical trials related to Metastatic Solid Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03993873 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

SHIELD-1
Start date: September 21, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)

NCT ID: NCT03893955 Active, not recruiting - Cancer Clinical Trials

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: May 21, 2019
Phase: Phase 1
Study type: Interventional

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.

NCT ID: NCT03059823 Active, not recruiting - Clinical trials for Metastatic Solid Tumors

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Start date: November 15, 2016
Phase: Phase 1
Study type: Interventional

The primary goal of this Phase 1 study is to characterize the safety and tolerability of INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on either every two week or every four week schedules of administration among patients with solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of INCMGA00012 will also be assessed. The purpose of Amendment 5 is to obtain additional safety experience at the newly defined recommended Phase 2 dose of 500 mg every 4 weeks in patients with endometrial cancer, specifically either microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Additionally, every 3 week (Q3W) flat-dosing will be studied in an additional tumor agnostic cohort.

NCT ID: NCT01543763 Active, not recruiting - Clinical trials for Metastatic Solid Tumors

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Start date: June 25, 2012
Phase: Phase 1
Study type: Interventional

This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.